NHS

News

UK access disparity resolved as NICE backs RCC therapy

Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and Bristol-Myers Squibb’s Opdivo will now be ab

News

Surprise Enhertu rejection follows NICE process change

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described

News

Pfizer’s Litfulo becomes first NHS drug for alopecia areata

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition t

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

EDI in clinical research: The case for adaptive strategies a...

The topic of Equality, Diversity, and Inclusion (EDI) in health and care research participation has been gaining traction in the past few years.

News

Public want data stored in UK amid security concerns

A VMware study has revealed that over half of the UK public trust the NHS to store and analyse their patient data safely, but where that data is stored is of pressing conc

UK access disparity resolved as NICE backs RCC therapy

Surprise Enhertu rejection follows NICE process change

Pfizer’s Litfulo becomes first NHS drug for alopecia areata

EDI in clinical research: The case for adaptive strategies a...

Public want data stored in UK amid security concerns

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

NHS

Editor's Picks